摘要
目的探讨miRNA-497和Raf-1在多发性骨髓瘤(MM)骨髓中的表达水平及其意义。方法选取2015年1月-2017年8月住院多发性骨髓瘤初诊患者52例和正常对照组30例作为研究对象,采用定量逆转录-聚合酶链反应法检测骨髓单个核miRNA-497的表达水平,免疫组织化学法检测Raf-1表达水平。结果 miRNA-497在MM中明显低于正常对照组;Raf-1蛋白在MM中明显高于正常对照组;不同期别MM的miR-497及Raf-1蛋白的表达水平之间进行比较,差异均有统计学意义(P<0.05)。结论 miR-497和Raf-1的表达与多发性骨髓瘤患者的发病机制、疾病进展相关,可以作为MM的疾病进展及预后判断指标。
Objective To explore the expression and clinical value of micro RNA-497 and Raf-1 in multiple myeloma（MM） patients. Methods Totally 52 hospitalized MM patients and 30 normal controls were selected as the research objects from January 2015 to August 2017. The expressions of microRNA-497 in bone marrow mono-nuclear cells of MM patients and normal controls were examined by reverse transcription quantitative polymerase chain reaction（RT-qPCR） , and the expressions of Raf-1 were examined by immunohistochemistry. Results The expression of miRNA-497 in MM patients were obviously lower than that in the control group; the expression of Raf-1 in MM patients were obviously higher than that in the control group ; the expressions of miR-497 and Raf-1 were compared in different stages of MM patients, with the differences statistically significant （P〈O.05）. Conclusion The expressions of miR-497 and Raf-1 are correlated to the pathogenesis and progression of MM patients, which can be a predictor of disease progression and efficacy in MM.
作者
戴梦璐
方炜
DAI Menglu;FANG Wei(Clinical Laboratory,Huzhou Central Hospital,Huzhou,Zhejiang 313000,China)
出处
《中国卫生检验杂志》
CAS
2018年第14期1738-1740,共3页
Chinese Journal of Health Laboratory Technology
